Aurobindo Pharma Ltd

Aurobindo Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1218.8, up 0.71% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.26% on the day, quoting at 25811.05. The Sensex is at 84221.24, down 0.3%. Aurobindo Pharma Ltd has gained around 9.9% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 3.23% in last one month and is currently quoting at 22686.8, up 0.36% on the day. The volume in the stock stood at 10.7 lakh shares today, compared to the daily average of 13.98 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1223.1, up 0.95% on the day. Aurobindo Pharma Ltd is down 1.34% in last one year as compared to a 10.05% jump in NIFTY and a 5.69% jump in the Nifty Pharma index.The PE of the stock is 35.05 based on TTM earnings ending September 25.Powered by Capital Market - Live

Aurobindo Pharma has received the Establishment Inspection Report (EIR) issued by the USFDA classifying Unit 1 of Apitoria Pharma, a wholly owned subsidiary of the company as 'Voluntary Action Indicated (VAI)'. Powered by Capital Market - Live

Net profit of Aurobindo Pharma rose 3.80% to Rs 848.45 crore in the quarter ended September 2025 as against Rs 817.38 crore during the previous quarter ended September 2024. Sales rose 7.73% to Rs 8236.96 crore in the quarter ended September 2025 as against Rs 7646.21 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales8236.967646.21 8 OPM %20.3720.48 - PBDT1705.111589.74 7 PBT1275.921207.46 6 NP848.45817.38 4 Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1112, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.56% on the day, quoting at 26080.4. The Sensex is at 85005.24, up 0.45%. Aurobindo Pharma Ltd has risen around 2.59% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 4.61% in last one month and is currently quoting at 22250.9, up 0.87% on the day. The volume in the stock stood at 8.82 lakh shares today, compared to the daily average of 11.47 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1121.2, up 1.33% on the day. Aurobindo Pharma Ltd is down 20.86% in last one year as compared to a 7.15% spurt in NIFTY and a 0.31% spurt in the Nifty Pharma index.The PE of the stock is 32.59 based on TTM earnings ending June 25.Powered by Capital Market - Live

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live

The newly formed entity aims to expand Aurobindo Pharma's pharmaceutical products business in Chile. The company stated that no governmental or regulatory approvals were required for the incorporation. The subsidiary has been incorporated with an initial share capital of CLP 1,000,000 (approximately USD 1,050), divided into 100 shares with a nominal value of CLP 10,000 each. Eugia Pharma B.V. has subscribed to 100% of the share capital in cash, thereby holding full ownership of the Chilean entity. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit tumbled 10.3% to Rs 824.75 crore despite a 4.5% increase in revenue from operations to Rs 7791.77 crore in Q1 FY26 over Q1 FY25. Powered by Capital Market - Live

Aurobindo Pharma announced that S. Venkatesh Kumar, Associate Vice President, a Senior Management person of the Company vide his letter dated 03 July 2025 tendered his resignation and the Company has accepted his resignation and he has been relieved from his duties with effect from the close of business hours on 30 September 2025.Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1097, up 4.45% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.1% on the day, quoting at 24997.1. The Sensex is at 81530.73, up 0.13%. Aurobindo Pharma Ltd has gained around 3.67% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 2.11% in last one month and is currently quoting at 22122.05, up 0.41% on the day. The volume in the stock stood at 32.48 lakh shares today, compared to the daily average of 13 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1100.1, up 4.22% on the day. Aurobindo Pharma Ltd is down 29.74% in last one year as compared to a 1.54% slide in NIFTY and a 5.19% slide in the Nifty Pharma index.The PE of the stock is 31.13 based on TTM earnings ending June 25.Powered by Capital Market - Live

The inspection, covering both oral solids and injectable units, was conducted between 25 August and 5 September 2025. At the conclusion, the USFDA issued a Form 483 citing eight procedural observations. The company clarified that the observations are procedural in nature and do not affect its financials or operations. Aurobindo added that it will submit a detailed response to the USFDA within the stipulated timelines. 'The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe,' it said. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit tumbled 10.3% to Rs 824.75 crore despite a 4.5% increase in revenue from operations to Rs 7791.77 crore in Q1 FY26 over Q1 FY25. Shares of Aurobindo Pharma rose 0.23% to Rs 1,046.85 on the BSE.Powered by Capital Market - Live

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys', its trastuzumab biosimilar version. Earlier in July 2025, Dazublys' has received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ's fourth biosimilar to be approved by MHRA after the approval of Bevqolva' in December 2024 and Zefylti' in May 2025 and Dyrupeg' in June 2025. Dazublys', Zefylti', and Dyrupeg' are also approved in the European Union.Powered by Capital Market - Live